1276663-01-4

Upstream product

• 541-47-9 3-Methylbutenoic acid 
• 937-00-8 3-trifluoromethyl-thiophenol 
• 1276662-90-8 3-methyl-3-((3-(trifluoromethyl)phenyl)sulfonyl)butyl methanesulfonate 
• 1276663-00-3 1-((4-azido-2-methylbutan-2-yl)sulfonyl)-3-(trifluoromethyl)benzene 
• 1276662-82-8 3-methyl-3-((3-(trifluoromethyl)phenyl)thio)butanoic acid 
• 1276662-86-2 3-methyl-3-((3-(trifluoromethyl)phenyl)sulfonyl)butanoic acid 
• 1276662-87-3 methyl 3-methyl-3-((3-(trifluoromethyl)phenyl)sulfonyl)butanoate 
• 1276662-89-5 3-methyl-3-((3-(trifluoromethyl)phenyl)sulfonyl)butan-1-ol 

Downstream Products

• 1276663-02-5 tert-butyl (3-methyl-3-(3-(trifluoromethyl)phenylsulfonyl)butyl)carbamate 
• 1276663-07-0 tert-butyl methyl(3-methyl-3-((3-(trifluoromethyl)phenyl)sulfonyl)butyl)carbamate 
• 1276663-08-1 N,3-dimethyl-3-((3-(trifluoromethyl)phenyl)sulfonyl)butan-1-amine hydrochloride 
• 1374864-36-4 5-(3-methyl-3-((3-(trifluoromethyl)phenyl)sulfonyl)butyl)-2-(trifluoromethyl)-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one 

Relevant academic research and scientific papers

BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS

The invention relates to bisarylsulfone and dialkylarylsulfone compounds (e.g., compounds according to any of Formulas (I)-(IX) or compounds (1)-(227) of Tables 4 and 5) useful in treating conditions associated with calcium channel function, and particularly conditions associated with N-type calcium channel activity. The invention also relates to pharmaceutical compositions that include these bisarylsulfone compounds, as well methods for the treatment of conditions such as cardiovascular disease, epilepsy, cancer and pain.